ACINETOCLINIC

twitterlinkedin

ACINETOCLINIC

Transition to Clinical Investigation Phase for Licencing of the First Vaccine Against Drug Resistent Acinetobacter Baumannii

Vaccines against resistant bacteria are advanced thanks to the Acinetoclinic consortium and the RETOS program.

The Seville company Vaxdyn leads the Acinetoclinic consortium to advance the development of vaccines against resistant bacteria. Pharmaceutical Reig Jofre, an expert in the stabilization and production of biotechnological injectable products, will develop the galenic formulation of the flagship product of Vaxdyn, a vaccine based on complete cells of Acinetobacter baumannii without endotoxins, which would allow its use in humans. The vaccine has been effective in animal models, although efficacy studies will increase to complete the preclinical dossier.

The Catalan company DraconisPharma participates as a technological partner, evaluating the adaptive immune response through the development of new trials. Vaxdyn and the Institute of Biomedicine of Seville will extend the studies in different experimental models. The Technological Center Leitat (Barcelona) will use the battery of antibodies against A. baumannii generated by Vaxdyn to develop two diagnostic biosensors of the infection with applicability in the preclinical analysis and in the follow-up of vaccinated or infected patients.

Project Budget: 1'094'583,93 €

Financial Framework: RETOS COLABORACIÓN

Contract number: RTC-2016-5161-1

Start Date: 01/06/2016

End Date: 30/06/2019

Partners:

Contact Manager: S. Nieva

The project ACINETOCLINIC, with file number RTC-2016-5161-1, approved in the 2016 Call for the State Program of R + D + i, oriented to the Challenges of the Society, has been financed by the Ministry of Economy, Industry and Competitiveness and co-financed through European Union FEDER funds with the main objective of Promoting technological development, innovation and quality research.